lazertinib 80 MG Oral Tablet
- RxCUI
- 2691156
- RxNorm name
- lazertinib 80 MG Oral Tablet
- Display name
- lazertinib 80 MG Oral Tablet
- Full name
- lazertinib 80 MG Oral Tablet
- Term type
- SCD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:20
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| LAZCLUZE | LAZERTINIB | Janssen Biotech, Inc. | c417f9ee-2027-4ed5-92ad-3c19266de16c | 2026-05-05 | Warnings, Adverse reactions | 2691156 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| c417f9ee-2027-4ed5-92ad-3c19266de16c | lazertinib 80 MG Oral Tablet | SCD | 6 | These highlights do not include all the information needed to use LAZCLUZE safely and effectively. See full prescribing information for LAZCLUZE. LAZCLUZE ® (lazertinib) tablets, for oral use Initial U.S. Approval: 2024 | 20260505 |
| c417f9ee-2027-4ed5-92ad-3c19266de16c | lazertinib 80 MG (equivalent to lazertinib mesylate 93.86 MG) Oral Tablet | SY | 6 | These highlights do not include all the information needed to use LAZCLUZE safely and effectively. See full prescribing information for LAZCLUZE. LAZCLUZE ® (lazertinib) tablets, for oral use Initial U.S. Approval: 2024 | 20260505 |
| c417f9ee-2027-4ed5-92ad-3c19266de16c | lazertinib 80 MG Oral Tablet | PSN | 6 | These highlights do not include all the information needed to use LAZCLUZE safely and effectively. See full prescribing information for LAZCLUZE. LAZCLUZE ® (lazertinib) tablets, for oral use Initial U.S. Approval: 2024 | 20260505 |